ArticleVaccine2007
A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects.Microorganisms · 2025Review
- Progress toward a vaccine for extraintestinal pathogenicInfection and immunity · 2024Article
- Urinary Tract Infections Caused by UropathogenicInternational journal of molecular sciences · 2023Review
- The Diversity ofMicroorganisms · 2023Review
- Evaluation of Recombinant AttenuatedFrontiers in immunology · 2017Article
- Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.Microbiology spectrum · 2016Review
- The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.Infection and immunity · 2013Article
- Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.Expert review of vaccines · 2012Review
- The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.Infection and immunity · 2010Article
- A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice.Infection and immunity · 2010Article
- Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Waging war against uropathogenic Escherichia coli: winning back the urinary tract.Infection and immunity · 2010Review
- Mucosal immunization with iron receptor antigens protects against urinary tract infection.PLoS pathogens · 2009Article
- Vaccines against extraintestinal pathogenicGut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Infections due to extraintestinal pathogenic E. coli (ExPEC) result in significant morbidity, mortality and increased healthcare costs. An efficacious vaccine against ExPEC would be desirable. In this report, we explore the use of killed-whole E. coli as a vaccine immunogen. Given the diversity of capsule and O-antigens in ExPEC, we have hypothesized that alternative targets are viable vaccine candidates. We have also hypothesized that immunization with a genetically engineered strain that is deficient in the capsule and O-antigen will generate a greater immune response against antigens other than the capsular and O-antigen epitopes than a wild-type strain. Lastly, we hypothesize that mucosal immunization with killed E. coli has the potential to generate a significant immune response. In this study, we demonstrated that nasal immunization with a formalin-killed ExPEC derivative deficient in capsule and O-antigen results in a significantly greater overall humoral response compared to its wild-type derivative (which demonstrates that capsule and/or the O-antigen impede the development of an optimal humoral immune response) and a significantly greater immune response against non-capsular and O-antigen epitopes. These antibodies also bound to a subset of heterologous ExPEC strains and enhanced neutrophil-mediated bactericidal activity against the homologous and a heterologous strain. Taken together, these studies support the concept that formalin-killed genetically engineered ExPEC derivatives are whole cell vaccine candidates to prevent infections due to ExPEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.